MiR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10

Jianyong Zheng1, Peng Ge1,2, Xiaonan Liu1

  • 11 State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, China.

Insights

MicroRNA-136 (miR-136) is downregulated in gastric cancer peritoneal metastasis, promoting tumor spread. Restoring miR-136 inhibits metastasis by targeting HOXC10, offering a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) regulate various cellular processes, including oncogenesis.
  • The role of miRNAs in tumor metastasis, specifically gastric cancer peritoneal metastasis, is not well understood.
  • Gastric cancer peritoneal metastasis is a significant clinical challenge with limited therapeutic options.

Purpose of the Study:

  • To identify microRNAs involved in gastric cancer peritoneal metastasis.
  • To elucidate the functional role of miR-136 in gastric cancer peritoneal metastasis.
  • To investigate the molecular mechanism underlying miR-136's function in gastric cancer peritoneal metastasis.

Main Methods:

  • Microarray analysis to identify differentially expressed miRNAs in gastric cancer peritoneal metastasis.
  • In vitro and in vivo experiments to assess the functional role of miR-136 and HOXC10.
  • Luciferase reporter assays and Western blotting to confirm direct targeting of HOXC10 by miR-136.

Main Results:

  • MiR-136 was significantly downregulated in gastric cancer peritoneal metastasis tissues and cell lines.
  • Restoration of miR-136 inhibited gastric cancer cell migration, invasion, and peritoneal metastasis in vitro and in vivo.
  • HOXC10 was identified as a direct target of miR-136, and its knockdown mimicked the anti-metastatic effects of miR-136.
  • Overexpression of HOXC10 reversed the inhibitory effects of miR-136 on metastasis.

Conclusions:

  • MiR-136 acts as a tumor suppressor in gastric cancer peritoneal metastasis by inhibiting HOXC10.
  • MiR-136 downregulation is associated with increased peritoneal metastasis and poor prognosis in gastric cancer patients.
  • MiR-136 represents a potential therapeutic target for gastric cancer peritoneal metastasis.